GLUD2

Across TCGA pan-cancer cohorts, GLUD2 mass-spec protein is linked to patient survival in 4 of 34 cancer types, making it a survival-associated GLUD2 data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in lung squamous cell carcinoma (LSCC), where higher GLUD2 mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated GLUD2 expression acts as an unfavorable survival marker, although some lineages such as LUAD and GBM show a favorable association.

LSCC, PDAC, and LUAD are the cancer types where GLUD2 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LSCC	DFS	Median	All	0.523	0.990	.008	4	view →
PDAC	DFS	Median	IV	0.250	0.934	.024	3	view →
LUAD	DFS	Median	II,III,IV	0.844	0.240	.048	2	view →
GBM	DFS	Tertile	All	0.923	0.480	.009	2	view →

Pink = unfavorable, green = favorable. Showing the 4 strongest of 4 lineages.

GLUD2–LSCC (DFS)

Open the LSCC breakdown →